> Is this really a pharmaceutical issue or a societal structure and support issue. This seems like a weak criticism. You're vaguely referring to some other hy

> Is this really a pharmaceutical issue or a societal structure and support issue. This seems like a weak criticism. You're vaguely referring to some other hypothetical solution that may or may not exist. There may be a case for a two-pronged approach, but why complain about the prong that just got approved?